Researchers recently looked at the efficacy of FDA-approved drugs and found that many of the pricey medications may be doing absolutely nothing for patients. In other pharmaceutical news: gender inequality in drug and medical trials, an experimental treatment never before tried in humans, and a look at upcoming cancer therapies.
from Kaiser Health News http://bit.ly/2KgQ2t1
May 31, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Bye-Bye to Health Insurance ‘Birthday Rule’? Kansas Lawmaker Floats FixWhen Kayla Kjelshus gave birth to her first child, the infant spent seven days in the neonatal intensive care unit, known as the NICU. This stressful medical experience was followed by an equally stressful financial one. Beca… Read More
Covid Renews Interest in Radiation, but Docs Caution Against Pilgrimages to Radon-Filled MinesBOULDER, Mont. — Twice a year, Brian Tichenor makes the 1,200-mile drive each way from his home in Kansas to a defunct uranium mine in Montana, where he takes an elevator 85 feet below the surface to sit amid radioactive rado… Read More
Sign-Up Window for Free COBRA Coverage for Many Laid-Off Workers Closes This WeekAfter being laid off from her job as a systems analyst for a specialty chemicals company in December, Gabriela de Pompignan opted to hang on to her former employer’s insurance coverage under the federal law known as COBRA. Ty… Read More
Women Say California Insurer Makes It Too Hard to Get Drug for Postpartum DepressionWhen Miriam McDonald decided she wanted to have another baby at age 44, her doctor told her she had a better chance of winning the lottery. So when she got pregnant right away, she and her husband were thrilled. But within th… Read More
Unraveling the Mysterious Mutations That Make Delta the Most Transmissible Covid Virus YetUpon first inspection, the mutations in the highly contagious delta covid variant don’t look that worrisome. For starters, delta has fewer genetic changes than earlier versions of the coronavirus. “When people saw that the ep… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment